Scoop has an Ethical Paywall
Merck Statement on COX-2 Inhibitors
Friday 29 April 2005
Alister Brown, managing director of Merck Sharp & Dohme New Zealand (MSD NZ), made the following comments in response to today’s announcement by the Ministry of Health that COX-2 inhibitors will remain available in New Zealand:
“At this time, Medsafe has issued new prescribing advice for selective Cox-2 inhibitor medicines, including ARCOXIA® (etoricoxib).
“We welcome the decision by Medsafe that will allow ARCOXIA to remain as a prescribing option in New Zealand. We are reviewing the actions of Medsafe and look forward to our discussions with the agency with respect to ARCOXIA.
“MSD NZ is continuing studies to further establish the long-term cardiovascular and overall safety profile of ARCOXIA.”
ENDS
Advertisement - scroll to continue reading
LAWA: “Know Before You Go” – Check Summer Swimming Water Quality Online
Official Aotearoa Music Charts: 2024 End Of Year Charts Have Been Published
Nielsen Book NZ: Nielsen BookData Announces 'In Too Deep' Is The Official New Zealand Number 1 Christmas Bestseller
PHARMAC: Pharmac Consulting On Six Medicines For New Zealanders
Athletics New Zealand: Funding Boost Propels Athletics NZ Toward LA 2028 Success
Te Whatu Ora Health New Zealand: Large Numbers Of RSE Workers Get Immunised To Protect Pacific Island Nations